In 1906, two English biochemists, Arthur Harden and William Young, were studying the fermentation of brewer's yeast when they isolated a compound they named "cozymase." It would take decades for biochemistry to understand what that substance would become: NAD+, nicotinamide adenine dinucleotide, a molecule now known to take part in more than 500 biological reactions, from cellular energy production to DNA repair. The problem, documented since the 2000s, is that its level declines with age. The most studied solution is to supply the body with one of its direct precursors — a molecule cells know how to convert into NAD+. Two candidates dominate the field: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). They are structurally almost identical — NMN is essentially NR with an extra phosphate group. But "almost identical" on paper doesn't mean equivalent in practice. Here's what ten years of research, compared molecule by molecule, actually allow us to say.
Two Routes to the Same Destination
NAD+ can't be swallowed directly: the molecule is too large and too electrically charged to cross the intestinal wall intact. The body has to rebuild it itself, from smaller precursors. NR and NMN are two consecutive steps on that same assembly line, positioned just before the finish line: NR → NMN → NAD+. Taking one or the other means, in theory, entering the assembly line at two different stations, one step apart.
On paper, the case for NMN seems airtight: it's closer to the finished product, so it should require fewer conversion steps. That's the most-repeated marketing argument of the past decade. It turns out to be far more fragile than it looks, as the next section shows.
Do Both Actually Raise NAD+? And at What Dose?
Before going further, let's answer the most direct question: do both molecules deliver on their basic promise? Yes, both of them do. But the full answer comes down to one word: dose. A dramatic number, stripped of its dosing context, means nothing — and that's exactly the mistake many articles on this topic make.
For NR, the very first human study tested three single doses in the same trial: 100, 300, and 1,000 mg (Trammell et al., 2016). Result: the rise in blood NAD+ is directly proportional to the dose — the higher the dose, the stronger the effect. The most dramatic increases reported in the literature come from the highest doses tested, as do the chronic-supplementation trials that confirmed and extended that effect: six weeks at 1,000 mg per day in middle-aged and older adults (Martens et al., 2018), three weeks at 1,000 mg per day in the skeletal muscle of older men (Elhassan et al., Cell Reports, 2019). At 300 mg per day — the dose found in a daily micronutrition formula like ours — the effect is real and dose-dependent, but more modest than the figures obtained at three times that dose. This is an essential point of rigor: comparing a daily 300 mg dose to results obtained at 1,000 mg would mean comparing different things.
For NMN, the reference trial tested 250 mg per day for twelve weeks and measured a 2.57-fold rise in whole-blood NAD+ (Igarashi et al., npj Aging, 2022) — a dose, this time, close to what's used for NR in common formulas. One nuance is worth flagging: in the landmark trial in postmenopausal women with prediabetes, also at 250 mg per day, NMN raised NAD+ in blood cells but not in skeletal muscle itself — even as insulin sensitivity improved (Yoshino et al., Science, 2021). A useful reminder: a rise in blood NAD+ and a rise in tissue NAD+ aren't always the same thing, for either molecule.
The real lesson of this section, then, isn't "NR performs better" or "NMN performs better" on this one criterion. It's that dose changes everything, and an honest comparison has to be made dose by dose, never number against number stripped of context. What can be said without that caveat, however, concerns something else entirely: how long each molecule has been studied, across how many people and conditions, and under what legal framework.
A Ten-Year Gap, Not a Detail
Did you know? The very first human study on NR was published in 2016. Samuel Trammell's team, at the University of Iowa, tested three oral doses (100, 300, and 1,000 mg) and observed a dose-dependent rise in blood NAD+ (Trammell et al., Nat Commun, 2016). Two years later, in 2018, a team at the University of Colorado published the first chronic-supplementation trial: six weeks of NR, double-blind against placebo, in healthy middle-aged and older adults — well tolerated, with a confirmed rise in NAD+ (Martens et al., Nat Commun, 2018). Since then, NR has been tested in trials covering peripheral artery disease (Nat Commun, 2024) and, at high dose, Parkinson's disease (the NR-SAFE trial, Nat Commun, 2023) — nearly a decade of published clinical trials, across varied populations and durations.
The first human study on NMN, meanwhile, dates from 2020. It involved ten healthy Japanese men, given a single dose (100, 250, or 500 mg), with a five-hour follow-up (Irie et al., Endocr J, 2020). Four years behind the first NR study, then — and a far narrower starting protocol: a single dose, a tiny sample, a few hours of observation, where NR had already tested multiple doses and, by 2018, sustained supplementation. Since 2020, NMN trials have multiplied, particularly in Japan and China, but the body of evidence remains, to date, noticeably younger and less diverse than NR's.
One Path the Science Knows, Another Still Debated
Here's the point least known to the public, and yet the most telling. To enter a cell, NR uses well-identified doors: nucleoside transporters called ENT1, ENT2, and ENT4, described and confirmed by several independent teams. This mechanism is not disputed in the literature.
For NMN, the story is different. In 2019, one team proposed the existence of a dedicated transporter, called Slc12a8, capable of bringing NMN directly into the cell without going through NR (Kim et al., Nat Metab, 2019). The same year, another team published a reply bluntly titled "Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter" — concluding that the available genetic, pharmacological, and kinetic evidence instead shows that extracellular NMN is first dephosphorylated into NR, by an enzyme called CD73, before it can enter the cell (Grozio et al., Nat Metab, 2019). The authors of the original study responded, maintaining their position using isotopic tracing. The debate, to this day, remains unresolved in the literature.
In other words: a significant part of the scientific community holds that NMN must, at least in part, convert back into NR before it even reaches the inside of the cell. If that hypothesis is correct, NR isn't merely an alternative to NMN — it may be the required intermediate that NMN itself has to pass through.
What the Law Says, Today
Beyond the mechanism, there's a simpler fact to verify: regulatory status. In Europe, nicotinamide riboside chloride has been authorized as a novel food since 2020 (Commission Implementing Regulation (EU) 2020/16), following a full assessment of its safety and bioavailability by the European Food Safety Authority (EFSA). That authorization was then extended in 2022 to new categories of use, up to 300 mg per day for the general population and 500 mg per day in certain regulated nutritional products (Commission Implementing Regulation (EU) 2022/1160).
NMN, meanwhile, is still not authorized as a novel food in the European Union as of this writing. EFSA published a favorable safety opinion in May 2026 — a necessary step, but not the same as authorization: it's an opinion, not a commercial green light. Market entry still requires a European Commission implementing act, following consultation with member states, which had not yet been published at the time this article was written. Six years, then, currently separate the entry into force of NR's legal framework from NMN's, which remains incomplete.
What Scientific Caution Recommends
It would be dishonest to conclude that NMN is dangerous: the available studies, including the 2020 trial, reported no concerning safety signal, and research on this molecule is advancing every year. The real picture isn't "effective versus ineffective" or "safe versus dangerous." It's more precise, and more useful, than that: on one side, a molecule with ten years of published human track record, an established cellular entry mechanism, and a complete European regulatory framework in place for six years. On the other, a promising molecule, but one whose clinical history remains young, whose route into the cell is still debated in the literature, and whose legal status in Europe remains, to date, pending.
For a supplement meant to be taken over the long term — a daily habit, not a one-off trial — that gap in track record isn't a cosmetic detail. It's precisely the kind of difference a rigorous formulation can't afford to ignore.
What to Take Away
NR and NMN aim for the same goal: supporting the NAD+ pool, that molecule Harden and Young crossed paths with, unknowingly, over a century ago, and whose importance the biology of aging has kept sharpening ever since. But aiming for the same goal doesn't mean starting from the same point. NR has a decade of published clinical trials, an undisputed cellular mechanism, and a stable European legal framework since 2020. NMN is progressing, but its evaluation remains, to date, ongoing — in the scientific literature as much as in the Official Journal of the European Union. This isn't an opinion: it's what the dates, the trial protocols, and the regulatory texts, laid side by side, show for themselves.
This article is published for informational and educational purposes. It does not constitute medical advice and does not replace consultation with a healthcare professional.
